1-(2-pentyl-phenyl)-ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-pentyl-phenyl)-ethanone
• 英文别名: 1-(2-Pentylphenyl)ethanone
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: LXAUWLQUPWIWGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  反-2-戊烯 在 [RhCl(PPh₃)3]Cl 盐酸 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 1-(2-pentyl-phenyl)-ethanone
  参考文献：
  名称：

  螯合辅助的Rh（I）催化的芳香族酮亚胺或酮与烯烃的邻烷基化。

  摘要：

  本文描述的是芳族酮亚胺或酮与烯烃的Rh（I）催化的邻烷基化。该方法对包括烯烃烯丙基质子，α，ω-二烯和内烯烃的1-烯烃在内的各种烯烃显示出高反应活性和对单烷基化的选择性。为了进行机理研究，进行了H / D交换实验，结果表明，即使在45°C的低温下，邻位CH键也很容易断裂。该反应的关键步骤是形成稳定的五元链通过螯合辅助邻位CH键活化的金属环。此外，通过添加50mol％的苄胺作为螯合辅助工具，成功实现了Rh（I）配合物与芳族酮的直接邻烷基化。

  DOI：

  10.1002/1521-3765(20020118)8:2<485::aid-chem485>3.0.co;2-1

文献信息

• PROCESS FOR PREPARATION OF NORBORNENE DERIVATIVES
  申请人：JX Nippon Oil & Energy Corporation

  公开号：EP2444386A1

  公开（公告）日：2012-04-25

  A method for producing a norbornene derivative, comprising: a first step of forming a Mannich base by reacting a carbonyl compound and an amine compound with each other in an acidic solvent, to thereby obtain a reaction liquid comprising the Mannich base in the acidic solvent, the acidic solvent comprising a formaldehyde derivative and 0.01 mol/L or more of an acid represented by the formula: HX (In the formula, X represents F or the like), the carbonyl compound being represented by any of the following general formulae (1) to (3): [in formulae (1) to (3), R1, R2, R3, R4, R5, and R6 each independently represent a hydrogen atom or the like, and n represents an integer of any of 0 to 4], the amine compound being represented by the following general formula (4): [in the formula (4), R7S each independently represent a linear chain saturated hydrocarbon group having 1 to 20 carbon atoms or the like, and X- represents F- or the like], the Mannich base being represented by any of the following general formulae (5) to (7): [R1, R2, R3, R4, R5, R6, and n in the formulae (5) to (7) have the same meanings as those of R1, R2, R3, R4, R5, R6, and n in the formulae (1) to (3), and R7 and X- in the formulae (5) to (7) have the same meanings as those of R7 and X- in the formula (4)] and a second step of reacting the Mannich base and a diene compound with each other by adding an organic solvent, a base in an amount of 1.0 to 20.0 equivalents to the acid, and the diene compound to the reaction liquid, and then heating the reaction liquid, to thereby form a norbornene derivative, the diene compound being represented by the following general formula (8): [in the formula (8), R8 represents a hydrogen atom or the like], the norbornene derivative being represented by any of the following general formulae (9) to (11): [R1, R2, R3, R4, R5, R6, and n in the formulae (9) to (11) have the same meanings as those of R1, R2, R3, R4, R5, R6, and n in the formulae (1) to (3), and R8 in the formulae (9) to (11) has the same meaning as that of R8 in the formula (8)].

  一种制备去氢莰烯衍生物的方法，包括以下步骤：第一步，在酸性溶剂中使羰基化合物和胺基化合物反应，形成曼尼希碱，从而在酸性溶剂中获得包含曼尼希碱的反应液，所述酸性溶剂包括甲醛衍生物和代表为HX的酸，其中HX中的X代表F或类似物，所述羰基化合物由以下通式（1）至（3）中的任一通式表示：[在通式（1）至（3）中，R1、R2、R3、R4、R5和R6各自独立地代表氢原子或类似物，n代表0至4中的任一整数]，所述胺基化合物由以下通式（4）表示：[在通式（4）中，R7S各自独立地代表具有1至20个碳原子或类似物的线性链饱和碳氢基团，X-代表F-或类似物]，所述曼尼希碱由以下通式（5）至（7）中的任一通式表示：[在通式（5）至（7）中，R1、R2、R3、R4、R5、R6和n的含义与通式（1）至（3）中的R1、R2、R3、R4、R5、R6和n的含义相同，通式（5）至（7）中的R7和X-的含义与通式（4）中的R7和X-的含义相同]；第二步，通过向反应液中加入有机溶剂、相当于酸的1.0至20.0当量的碱和二烯化合物，然后加热反应液，使曼尼希碱与二烯化合物发生反应，从而形成去氢莰烯衍生物，所述二烯化合物由以下通式（8）表示：[在通式（8）中，R8代表氢原子或类似物]，所述去氢莰烯衍生物由以下通式（9）至（11）中的任一通式表示：[在通式（9）至（11）中，R1、R2、R3、R4、R5、R6和n的含义与通式（1）至（3）中的R1、R2、R3、R4、R5、R6和n的含义相同，通式（9）至（11）中的R8的含义与通式（8）中的R8的含义相同]。
• Sulfonic acids, their derivatives and pharmaceutical compositions containing them
  申请人：Dompé S.P.A.

  公开号：EP1457485A1

  公开（公告）日：2004-09-15

  Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, the selected sulfonic acids and their derivativas are devoid of cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of damages caused by ischemia and reperfusion.

  选择性磺酸、它们的衍生物和含有这些化合物的药物组合物在抑制由白细胞介素-8（IL-8）与CXCR1和CXCR2膜受体相互作用引起的中性粒细胞（PMN白细胞）趋化活化方面是有用的。这些化合物用于预防和治疗由该活化引起的病理状况。值得注意的是，所选的磺酸及其衍生物不具有环氧化酶抑制活性，特别适用于治疗中性粒细胞依赖性病理状况，如银屑病、溃疡性结肠炎、黑色素瘤、慢性阻塞性肺疾病（COPD）、大疱性类天疱疮、类风湿性关节炎、特发性纤维化、肾小球肾炎以及预防和治疗缺血再灌注引起的损伤。
• [EN] NOVEL TRIENOIC RETINOID COMPOUNDS AND METHODS<br/>[FR] NOUVEAUX COMPOSES DE RETINOIDE TRIENOIQUE ET METHODES D'UTILISATION
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：WO1996020913A1

  公开（公告）日：1996-07-11

  (EN) Novel trienoic retinoid compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.(FR) L'invention porte sur des composés de rétinoïde triénoïque faisant preuve d'activité à l'égard de récepteurs d'acide rétinoïque et de récepteurs de rétinoïde X. Elle porte également sur des préparations pharmaceutiques contenant ces composés ainsi que sur leurs méthodes d'utilisation.

  (中文) 提供了具有对视黄酸受体和维甲酸X受体活性的新型三烯酸类维甲酸化合物。还提供了包含这些化合物的药物组合物和它们的使用方法。
• Novel pyridazine derivatives and medicines containing the same as effective ingredients
  申请人：Ohkuchi Masao

  公开号：US20050267113A1

  公开（公告）日：2005-12-01

  This invention relates to pyridazine derivatives represented by the formula (1): wherein R 1 represents a (substituted) aryl group, R 2 represents a phenyl group substituted at 4 -position by a lower alkoxyl group or a lower alkylthio group, R 3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4 -position and the 5 -position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin- 1 β production, and are useful as preventives and therapeutics for immmune system diseases, inflammatory diseases, ischemic diseases and the like.

  本发明涉及由式（1）表示的吡嗪衍生物：其中R1表示（取代）芳基基团，R2表示在4-位被低烷氧基基团或低烷硫基基团取代的苯基基团，R3表示低烷氧基基团、卤代低烷基基团、低环烷基基团、（取代）芳基基团、（取代）芳氧基基团、（取代）含氮杂环环残基、（取代）氨基甲酰基或低烷基甲酰基，A表示单键、低烷基亚ethylene基或低烷基亚烯基，X表示O或S，虚线表示4-位和5-位之间的碳-碳键为单键或双键，或其盐；以及包含它们作为有效成分的药物。这些化合物对白细胞介素-1β的产生有出色的抑制活性，并且可用作免疫系统疾病、炎症性疾病、缺血性疾病等的预防和治疗。
• NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS
  申请人：OHKUCHI Masao

  公开号：US20090270399A1

  公开（公告）日：2009-10-29

  This invention relates to pyridazine derivatives represented by the formula (1): wherein R 1 represents a (substituted) aryl group, R 2 represents a phenyl group substituted at 4-position by a lower alkoxyl, group or a lower alkylthio group, R 3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted) nitrogen-containing heterocyclic ring residue, a (substituted) aminocarbonyl group or a lower alkylcarbonyl group, A represents a single bond, a lower alkylene group or a lower alkenylene group, X represents O or S, and the dashed line indicates that the carbon-carbon bond between the 4-position and the 5-position is a single bond or a double bond, or salts thereof; and also to medicines containing them as effective ingredients. These compounds have excellent inhibitory activity against interleukin-1β production, and are useful as preventives and therapeutics for immune system diseases, inflammatory diseases, ischemic diseases and the like.

  本发明涉及由式（1）表示的吡嗪衍生物： 其中R1表示（取代的）芳基基团，R2表示在4位被低烷氧基团或低烷硫基团取代的苯基基团，R3表示低烷氧基团、卤代的低烷基团、低环烷基团、（取代的）芳基基团、（取代的）芳氧基基团、（取代的）含氮杂环环残基、（取代的）氨基甲酰基团或低烷基甲酰基团，A表示单键、低烷基烷基或低烯基烷基，X表示O或S，虚线表示4位和5位之间的碳-碳键为单键或双键，或其盐；以及含有它们作为有效成分的药物。这些化合物具有优异的抑制白细胞介素-1β产生的活性，可用作预防和治疗免疫系统疾病、炎症性疾病、缺血性疾病等。